Application of response surface methodology (RSM) in statistical optimization and pharmaceutical characterization of a patient compliance effervescent tablet formulation of an antiepileptic drug levetiracetam

Future Journal of Pharmaceutical Sciences

Table 3 Composition of levetiracetam effervescent tablets 500 mg

	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11	C12	C13	C14
Intragranular (for compaction)
Levetiracetam	500	500	500	500	500	500	500	500	500	500	500	500	500	500
Anhydrous lactose (lactose 21AN)	700	700	700	700	700	700	700	700	700	700	700	700	700	700
Colloidal silicon dioxide	16	16	16	16	16	16	16	16	16	16	16	16	16	16
Sodium benzoate	16	16	16	16	16	16	16	16	16	16	16	16	16	16
Sodium acetate	16	16	16	16	16	16	16	16	16	16	16	16	16	16
Extra granular
Mannitol (Pearlitol 200 SD)	286	286	286	286	286	286	286	286	286	286	286	286	286	286
Sorbitol (Neosorb® XTAB 300S )	220	220	220	220	220	220	220	220	220	220	220	220	220	220
Citric acid	640	1092.55	640	640	640	640	187.45	640	640	960	320	320	640	960
Effersoda	187.45	640	640	640	1092.55	640	640	640	640	960	320	960	640	320
Aspartame	60	60	60	60	60	60	60	60	60	60	60	60	60	60
Orange flavor	26	26	26	26	26	26	26	26	26	26	26	26	26	26
Colloidal silicon dioxide	16	16	16	16	16	16	16	16	16	16	16	16	16	16
Sodium benzoate	32	32	32	32	32	32	32	32	32	32	32	32	32	32
Sodium acetate	32	32	32	32	32	32	32	32	32	32	32	32	32	32
Total (mg)	2747.45	3652.55	3200	3200	3652.55	3200	2747.45	3200	3200	3840	2560	3200	3200	3200